Log In Sign up
The largest database of trusted experimental protocols

Mouse igg2a clone c1

Manufactured by BioXCell
Visit Supplier

Mouse IgG2a clone C1.18.4 is a monoclonal antibody that recognizes mouse IgG2a. It is suitable for use in various immunological applications, such as ELISA, flow cytometry, and immunoprecipitation.

Automatically generated - may contain errors

Lab products found in correlation

Hamster igg, by BioXCell (1 mentions) Hamster igg f ab 2 fragments, by BioXCell (1 mentions) Mouse igg1 clone mopc 21, by BioXCell (1 mentions) Rat igg2b, by BioXCell (1 mentions) Cd8 clone yts 169, by BioXCell (1 mentions) Nk1.1 clone pk136, by BioXCell (1 mentions) Cd4 clone gk1, by BioXCell (1 mentions) Orencia, by Bristol-Myers Squibb (1 mentions)

Spelling variants of this product

IgG2a (25 citations) Mouse IgG2a (17 citations) (clone C1.18.4, (9 citations) Mouse IgG2a isotype control (clone C1.18.4; (4 citations)

4 protocols using mouse igg2a clone c1

1

Monoclonal Antibodies for T Cell Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Monoclonal anti-mouse CD3 monoclonal antibodies (CD3-specific mAb; 145-2C11 or F(ab’)2 fragments of 145-2C11), anti-human CD3 mAb (OKT3) and the respective isotype controls (hamster IgG, hamster IgG F(ab’)2 fragments and mouse IgG2a clone C1.18.4) were purchased from BioXCell. The CD8 T cell epitopes GAD65524–543, proinsulin (PI) B15–23 and the BDC2.5 mimotope1040-31 (Mimo) were purchased from SynBioSci.
Kuhn C., Rezende R.M., da Cunha A.P., Valette F., Quintana F.J., Chatenoud L, & Weiner H.L. (2016). Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain. Journal of autoimmunity, 76, 115-122.
+ Open protocol
+ Expand
2

Antibody Blocking of CD8 T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For antibody blocking experiments of CD8 T cells from healthy donor peripheral blood, T cell reactivation was performed as described above. T cell reactivation was performed in the presence of CD11a antibody (1 μg/ml, clone R7-1, BioXCell), CD54 (1 μg/ml, clone R6-5-D6, BioXCell) antibody, CD178/FasL (10 μg/ml, Clone MFL3 (RUO), BD Pharmingen) or respective isotype controls (1 μg/ml, mouse IgG2a, clone C1.18.4 and mouse IgG1, clone MOPC-21, both BioXCell; 10 μg/ml, Armenian Hamster IgG1, κ, BD Pharmingen). New antibodies were added during every medium refresh.
Lin C.P., Levy P.L., Alflen A., Apriamashvili G., Ligtenberg M.A., Vredevoogd D.W., Bleijerveld O.B., Alkan F., Malka Y., Hoekman L., Markovits E., George A., Traets J.J., Krijgsman O., van Vliet A., Poźniak J., Pulido-Vicuña C.A., de Bruijn B., van Hal-van Veen S.E., Boshuizen J., van der Helm P.W., Díaz-Gómez J., Warda H., Behrens L.M., Mardesic P., Dehni B., Visser N.L., Marine J.C., Markel G., Faller W.J., Altelaar M., Agami R., Besser M.J, & Peeper D.S. (2024). Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness. Cancer Cell, 42(4), 623-645.e10.
+ Open protocol
+ Expand
3

Depletion of Immune Cells in Teratoma Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were bled (as described in the humanized mice section) prior to the first injection of depleting antibodies. Mice were injected intraperitoneally with 250µg of one of the following depleting antibodies: mouse IgG2a (clone C1.18.4; BioXCell), rat IgG2b (BioXCell), CD8 (clone YTS169.4; BioXCell), CD4 (clone GK1.5; BioXCell), CD20 (clone SA271G2; BioLegend), or NK1.1 (clone PK136; BioXCell). Four days after injection, mice were bled to confirm depletion. hESCs were transplanted into these mice 5d after the initial depleting antibody injection. Depleting antibodies were administered weekly throughout the teratoma assay.
Pizzato H.A., Alonso-Guallart P., Woods J., Johannesson B., Connelly J.P., Fehniger T.A., Atkinson J.P., Pruett-Miller S.M., Monsma FJ J.r, & Bhattacharya D. (2023). Engineering Human Pluripotent Stem Cell Lines to Evade Xenogeneic Transplantation Barriers. bioRxiv.
+ Open protocol
+ Expand
4

Modulating Immune Responses in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were treated with the following: 450 μg/dose (i.p.) of anti-mouse IL-2 mAb (clone S4B6-1; BioXCell) or PBS on d 0, 2, 4, and 6 and sacrificed on d 9; 250 μg/dose (i.p.) of human CTLA-4-Ig (Orencia; Bristol-Myers Squibb) or PBS on d 0, 2, 4, and 6 and sacrificed on d 8; 700 μg/dose (i.p.) of anti-mouse I-Ab mAb (clone Y-3P; BioXCell) or mouse IgG2a (clone C1.18.4) or PBS on d 0, 2, and 3 and sacrificed on d 6; 250 μg/dose (i.p.) of anti-mouse CTLA-4 mAb (clone UC10-4F10-11; BioXCell) or Armenian hamster IgG on d 0, 2, 4, and 6 and sacrificed on d 8. For co-treatment studies, mice were treated with CTLA-4-Ig on d 0, 2, and 4 along with anti-I-Ab mAb on d 0, 2, and 3 and sacrificed on d 6.
Holt M.P., Punkosdy G.A., Glass D.D, & Shevach E.M. (2017). TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis. Journal of immunology (Baltimore, Md. : 1950), 198(4), 1503-1511.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!